Gilead Sciences, Inc. GILD
At closeNov 12, 2026, 5:31 PM EST
After hours · Nov 12, 5:31 PM ET
- YTD
- +36.83%
- 1 year
- +36.10%
- Market cap
- 208.31B
- Revenue (ttm)
- 30.99B
- Profit margin
- -12.46%
- EPS (ttm)
- -3.13
- Shares out
- 1.24B
- Forward P/E
- 16.58
- Dividend
- 3.28 (1.92%)
- Ex-dividend date
- Dec 14, 2026
- YTD return
- +36.83%
- 1-year return
- +36.10%
- Volume
- 4.23M
- Avg volume
- 5.99M
- Open
- 171.18
- Previous close
- 169.73
- Day's range
- 167.93 – 171.70
- 52-week range
- 116.88 – 176.58
- Beta
- 0.37
- Analysts
- Buy
- Price target
- 174.77 (+4.1%)
- Earnings date
- Feb 9, 2027
5D +1.79 (+1.08%)
Key statistics
- Enterprise value
- 228.72B
- PEG ratio
- 2.29
- Price / sales
- 6.72
- Price / book
- 15.98
- Dividend yield
- 1.93%
- Payout ratio
- 43.46%
- Revenue growth
- 6.80%
- Free cash flow
- 10.68B
- Total cash
- 7.95B
- Total debt
- 26.23B
- Return on equity
- -22.45%
- Short % of float
- 1.72%
- 50-day average
- 154.40
- 200-day average
- 141.44
Analyst view
Consensus: buy
- Target (low)
- 131.00
- Target (mean)
- 174.77
- Target (high)
- 200.00
- Strong buy6
- Buy16
- Hold5
- Sell0
- Strong sell1
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate 1.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | 1.45 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.19 | 2.55 | +0.36 | +16.44% |
| Aug 3, 2026 | Jun 30, 2026 | -7.25 | -6.75 | +0.50 | +6.90% |
| May 7, 2026 | Mar 31, 2026 | 1.91 | 2.03 | +0.12 | +6.28% |
| Feb 10, 2026 | Dec 31, 2025 | 1.81 | 1.86 | +0.05 | +2.76% |
| Oct 30, 2025 | Sep 30, 2025 | 2.13 | 2.47 | +0.34 | +15.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | UBS | main | Buy | Buy |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | Citigroup | main | Buy | Buy |
| Oct 30, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Oct 30, 2026 | TD Cowen | main | Buy | Buy |
| Oct 30, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- gilead.com
News
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth? 
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat 
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat 
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript 
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch 
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? 
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? 
Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease 
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation 
Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?
Your note
Sign in to keep a note on GILD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTON JACQUELINE K | Director | Stock Award(Grant) | Apr 29, 2026 | 27,202 |
| BERGER DIETMAR P. | Officer | Conversion of Exercise of derivative security | Sep 9, 2026 | 19,522 |
| DICKINSON ANDREW D | Chief Financial Officer | Sale | Sep 14, 2026 | 164,096 |
| MANWANI HARISH | Director | Stock Award(Grant) | Apr 29, 2026 | 15,015 |
| MERCIER JOHANNA | Officer | Sale | Sep 14, 2026 | 116,684 |
| O'DAY DANIEL PATRICK | Chief Executive Officer | Sale | Nov 1, 2026 | 551,683 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.82% | 121,844,108 | 20.46B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 81,091,734 | 13.62B | Jun 29, 2026 |
| State Street Corporation | 4.94% | 61,216,552 | 10.28B | Jun 29, 2026 |
| FMR, LLC | 4.70% | 58,265,696 | 9.79B | Sep 29, 2026 |
| Capital World Investors | 3.30% | 40,988,975 | 6.88B | Jun 29, 2026 |
| Invesco Ltd. | 3.21% | 39,819,151 | 6.69B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 39,416,893 | 6.62B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 32,173,750 | 5.40B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 25,899,672 | 4.35B | Sep 29, 2026 |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 1.39% | 17,282,812 | 2.90B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 16,522,315 | 2.77B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 16,114,416 | 2.71B | Sep 29, 2026 |